Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The 'Europe Cell & Gene Therapy Market - Focused Insights 2024-2029' report has been added to ResearchAndMarkets.com's offering.The Europe Cell & Gene Therapy Market was valued at USD 2.26 billion in 2023, and is expected to reach USD 14.45 billion by 2029, rising at a CAGR of 36.24%.

都柏林，2024年6月20日（环球通讯社）--“欧洲细胞与基因治疗市场聚焦洞察2024-2029”报告已添加到ResearchAndMarkets.com的产品中。2023年欧洲细胞与基因治疗市场价值22.6亿美元，预计到2029年将达到144.5亿美元，复合年增长率为36.24%。

The Europe cell and gene therapy market report includes exclusive data on 36 vendors. The Europe cell & gene therapy market is highly competitive, driven by the increasing number of biopharmaceutical companies developing new therapies. Moreover, the rising financial support and government initiatives for regenerative medicines and advanced medicinal products boost key players in the market.

欧洲细胞和基因治疗市场报告包括36家供应商的独家数据。由于越来越多的生物制药公司开发新疗法，欧洲细胞与基因治疗市场竞争激烈。此外，不断增加的财政支持和政府对再生药物和先进医药产品的举措提振了市场的关键参与者。

Leading market players in the Europe CGT market are Novartis, Gilead Sciences, Amgen, F. Hoffmann-La Roche, Orchard Therapeutics, BioMarin Pharmaceutical, PTC Therapeutics, Bristol-Myers Squibb, Organogenesis, Smith & Nephew, Legend Biotech, CSL Ltd, Vertex Pharmaceuticals Inc, and Human Stem Cells Institute PJSC, which are competing with rapidly emerging market players in the market.

欧洲CGT市场的主要市场参与者是诺华、吉利德科学、安进、F.Hoffmann-La Roche、Orchard Therapeutics、BioMarin Pharmaceutical、PTC Therapeutics、百时美施贵宝、Organogenesis、Smith&Nephew、Legend Biotech、CSL Ltd、Vertex Pharmaceuticals Inc和人类干细胞研究所PJSC，它们正在与市场上迅速崛起的市场参与者竞争。

Vendors in the market are increasing their market share through inorganic growth. Germany held the largest share, over 21%, in the European cell and gene therapy market in 2023. Germany is at the forefront of cell and gene therapy due to major investments by the public and private sectors, which have boosted the development of the country's cell and gene therapy market.

市场上的供应商正在通过无机增长增加其市场份额。2023年，德国在欧洲细胞和基因治疗市场占有最大份额，超过21%。由于公共和私营部门的重大投资，德国在细胞和基因治疗方面处于领先地位，这推动了该国细胞和基因治疗市场的发展。

Germany is actively developing and testing innovative cell and gene therapy medicines, which offer patients vast benefits. Funding Support in Europe for CGTs: US companies have primarily driven the growth of investments in CGT projects in recent years. The US market saw a 53% increase in CGT investment in 2021 c.

德国正在积极开发和测试创新的细胞和基因治疗药物，为患者带来巨大益处。欧洲对CGT的资金支持：近年来，美国公司主要推动了CGT项目投资的增长。2021年，美国市场的CGT投资增长了53%。

Attachment

附件

European Cell & Gene Therapy Market

欧洲细胞与基因治疗市场